Latest news about Denis Chem Lab
Denis Chem Lab
69.65
-0.02(-0.03%)
Company Performance:
View Company Insights1D-0.03%
1M-4.95%
6M-8.85%
1Y-30.63%
5Y+24.04%
More news about Denis Chem Lab
06Apr 26
Denis Chem Lab Limited Files SEBI Compliance Certificate for Quarter Ended March 31, 2026
Denis Chem Lab Limited submitted its quarterly certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, to BSE Limited on April 6, 2026. The certificate was issued by registrar MUFG Intime India Private Limited, confirming compliance with dematerialization procedures and proper processing of securities within prescribed timelines. The pharmaceutical manufacturer, which produces parenteral products, fulfilled its regulatory obligations through Company Secretary Anal Desai's filing.
31Mar 26
Denis Chem Lab: Varun Daga Family Trust Files Substantial Acquisition Disclosure
Varun Daga Family Trust has filed a substantial acquisition disclosure under SEBI Regulation 29(1) for Denis Chem Lab Limited, acquiring 2,67,499 equity shares representing 1.93% stake through off-market transaction. The coordinated acquisition with persons acting in concert resulted in aggregate holdings of 13,37,498 shares (9.64%) of the company's paid-up equity share capital.
14Feb 26
Denis Chem Lab Limited Reports Strong Q3FY26 Results with 88.6% Profit Growth
Denis Chem Lab Limited announced strong Q3FY26 financial results with net profit rising 88.6% to ₹332.16 lakh and revenue increasing 6.2% to ₹4,551.83 lakh. The Board approved results on February 14, 2026, under SEBI regulations, with the company maintaining focus on transfusion solutions manufacturing.
13Aug 25
Denis Chem Lab Reports 19% Surge in Q1 Profit, Revenue Grows 4.9%
Denis Chem Lab Limited, a pharmaceutical company, announced strong Q1 FY2026 results. Net profit increased by 19% to Rs 247.50 crore, while revenue from operations grew 4.9% to Rs 4,327.59 crore. Earnings per share rose to Rs 1.78 from Rs 1.50 in the previous year. The company demonstrated effective cost management despite increased material costs. Managing Director Himanshu C. Patel highlighted the company's resilience and operational strength. Auditors Shah & Shah Associates issued an unmodified opinion on the financial results.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Laurus Labs
Dr Reddys Laboratories
Aurobindo Pharma
2,001.10
(+0.56%)
7,835.00
(+0.65%)
4,872.10
(-0.13%)
1,466.40
(-0.54%)
1,115.10
(-0.68%)
2,421.20
(-1.05%)
2,575.90
(-0.65%)
1,781.30
(0.0%)
1,144.80
(+0.22%)
1,576.30
(-0.91%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
